Render Target: STATIC
Render Timestamp: 2024-12-20T10:54:10.801Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-04-05 20:22:53.419
Product last modified at: 2024-11-22T17:45:08.491Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

CUEDC2 Antibody #12294

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H Mk
    SENSITIVITY Endogenous
    MW (kDa) 30-32
    SOURCE Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CUEDC2 Antibody recognizes endogenous levels of total CUEDC2 protein.

    Species Reactivity:

    Human, Monkey

    Source / Purification

    Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CUEDC2 protein. Antibodies are purified by protein A and peptide affinity chromatography.

    Background

    CUE domain-containing 2 (CUEDC2) protein is involved in regulating many cellular events including cell cycle regulation (1) and inflammation (2). Research studies have shown that CUEDC2 is highly expressed in many types of tumors, suggesting this protein may play a role in tumorigenesis (1,3). CUEDC2 is activated in early mitosis when it is phosphorylated by Cdk1 at Ser110. Phosphorylated CUEDC2 binds to Cdc20, which leads to the release of the anaphase-promoting complex/cyclosome (APC/C) from checkpoint inhibition, initiating anaphase. CUEDC2 is then dephosphorylated when cells exit mitosis (1). CUEDC2 is also an inhibitor of IKKα and IKKβ activation (2) as well as Jak1/Stat3 signaling (4). Research indicates that inappropriate regulation of CUEDC2 may contribute to tumor development by causing chromosome instability (1). Multiple studies have reported that CUEDC2 plays a role in the downregulation of progesterone receptor and estrogen receptor α, impairing the effects of progesterone on breast cancer cell growth. Conversely, research studies have shown that CUEDC2 and HER2 expression have a significant positive correlation in breast cancers, leading investigators to suggest that CUEDC2 could be an important target for breast cancer therapy (3,5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.